

SAMPLE PATIENT APPEAL LETTER
FOR PROMETHEUS® IBD Serology 7

(Please edit appropriately based upon your own information and medical history. Please notify Prometheus' Billing Department at (888) 892-8391 when filing an appeal as we may be able to assist.)

Note to Patient: *If coverage was denied by your Medical Group rather than your Insurance Carrier, this letter should be addressed to the Medical Director at the Medical Group with a copy to your Insurance Carrier.*

<DATE>

Red Cross Red Shield
P.O. Box 12345
Los Angeles, CA 90060

Regarding PROMETHEUS® IBD Serology 7 testing for:

Name:	Jane Doe	Claim #:	11111
Date of Birth:	February 25, 1969	Date of service:	July 4, 2007
Insurance ID:	XXXX123456789	Original Claim:	\$259.50
Policy Holder:	Mr. John Doe	Date of EOB:	July 31, 2007

(This letter will need to address each specific reason for denial or unacceptable payment listed on the insurance EOB.)

Dear Medical Appeals Reviewer:

I am writing to appeal your decision about medical coverage for the PROMETHEUS IBD Serology 7 diagnostic test that my gastroenterologist, Dr. Ulysses Grant at Sunnyvale Hospital in San Diego, CA ordered. Dr. Grant and I felt that this test was a medically necessary step in the diagnosis and treatment of my symptoms. I would like to address these coverage issues hoping that you will reconsider your decision given the new information listed below.

(Describe all information relevant to your symptoms and treatment)

I am 39 years old, and because of my symptoms of (*diarrhea, GI bleeding, abdominal pain, and nonspecific enteritis*) my doctor ordered the PROMETHEUS IBD Serology 7 to aid in my clinical evaluation and for additional information to make a more informed decision into my illness.

PROMETHEUS IBD Serology 7 helps diagnose inflammatory bowel disease (IBD) and differentiate between ulcerative colitis (UC) and Crohn's disease (CD). Knowledge of serologic markers may help determine more severe disease phenotypes, help predict disease behavior, and potentially avoid a costly workup. Serologic markers can also help predict response to some therapeutics. **(AND)** There is no in-network laboratory near me willing to refer this test or able to provide comparable testing. **(OR)** I utilized a network doctor and laboratory, but my blood sample was referred to Prometheus without my knowledge. I've included information about the PROMETHEUS IBD Serology 7 diagnostic test.

Please approve full coverage for the PROMETHEUS IBD Serology 7 or at least apply in-network benefit coverage waiving all out of network deductibles for laboratory testing. If necessary, please review these services for any "wrap around benefits" provided under my plan.

Thank you for your prompt attention. I look forward to receiving a written response from you within two weeks.

Sincerely,

Jane Doe
1234 Main Ave.
Los Angeles, CA 90210
XXX-XXX-XXXX

cc: Dr. Ulysses Grant

Attachments:

1. PROMETHEUS IBD Serology 7 Product Detail Sheet

For additional information about PROMETHEUS IBD Serology 7 or procedure code descriptions, contact Prometheus at 1-888-892-8391.



PROMETHEUS® IBD Serology 7 Cat # 1007

Product Description

PROMETHEUS® IBD Serology 7 is the most comprehensive inflammatory bowel disease (IBD) test available. Utilizing several proprietary and patented markers and incorporating sophisticated pattern recognition technology, results may help physicians diagnose IBD and differentiate between ulcerative colitis (UC) and Crohn's disease (CD). Knowledge of serologic markers may help determine more severe disease phenotypes, and help predict disease behavior.

- A quantitative analysis of bio-markers combined with the Smart Diagnostic Algorithm^b (pattern-recognition technology) for IBD prediction and differentiation
- PROMETHEUS IBD Serology 7 is only offered at Prometheus
- **Specimen Requirements** - Serum, 2.0 mL: SST or Red Top Tube
- **Shipping and Handling** - Ambient or refrigerated
- **Storage Conditions/Stability** - 7 days ambient; 14 days refrigerated
- **Turn Around Time** – 3 to 4 days
- **Reference Range: NOTE: Patient test results are based on the Smart Diagnostic Algorithm. Assay and reference values are provided for prognostic interpretation.**
 - ASCA IgA ELISA: <20.0 EU/mL
 - ASCA IgG ELISA: <40.0 EU/mL
 - Anti-OmpC^a IgA ELISA: <16.5 EU/mL
 - Anti-CBir1^a ELISA: <21.0 EU/mL
 - AutoAntibody ELISA: <12.1 EU/mL
 - IFA Perinuclear Pattern: Not Detected
 - DNase Sensitivity^a: Not Detected

Facilities Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- Prometheus is CLIA certified and CAP accredited. All laboratory tests have been validated in accordance with the guidelines established by these and other applicable agencies. Currently, Food and Drug Administration (FDA) approval is not required for IBD Serology 7 testing performed by Prometheus.

CPT Codes (as applied by Prometheus)

- **83520(X5)**, ELISA; antibody specific for each bio-marker. (*See above.*)
- **88347(X2)**, IBD specific pANCA, Indirect Immunofluorescent assays, IgG specific & DNase sensitivity.

Literature References

- Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. *Gastroenterology*. 2005;128:2020-2028.
- Abreu MT, et al. Use of serologic tests in Crohn's disease. *Clin Perspect Gastroenterol*. 2001;155-164.
- Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. *Gut*. 2001;49(5):671-677.
- Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics Vasiliauskas. *Gut*. 2000;47(4):487-496.
- Targan SR. The Utility of ANCA and ASCA in Inflammatory bowel disease. *Inflamm Bowel Dis*. 1999; 5(1):61-3.
- Ruemele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. *Gastroenterology*. 1998;115(4):822-829.

- a. patented
- b. patent pending